Bincy Abraham, MD
Gastroenterology · Houston, TXNPI 1578767166
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,097,315 of the $1,601,325 with a category attached, or 68.5%. 52 manufacturers reported payments, led by AbbVie at 26.2% of the total. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,149 payments — averaging $745.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$419K
- Pfizer$281K
- Takeda Pharmaceuticals U.S.A., Inc.$190K
- E.r. Squibb & Sons, L.L.C.$156K
- Johnson & Johnson$141K
- Lilly USA, LLC$120K
- plus $294K from 46 others
Across 199 payments — averaging $4738.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$146K
- Eli Lilly$112K
- AbbVie$107K
- Janssen Research & Development, LLC$103K
- Roche Products Limited$93K
- Takeda Pharmaceuticals U.S.A., Inc.$88K
- plus $294K from 8 others
What the payments were for
- Consulting fees$311,62419%
- Speaking & faculty fees$1,097,31569%
- Travel & lodging$149,7689%
- Food & beverage$41,9543%
- Education$6650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$208,945
- XELJANZ$207,550
- Skyrizi$177,098
- Entyvio$167,427
- ZEPOSIA$129,180
- Humira$108,729
- Tremfya$67,371
- ZYMFENTRA$66,121
- Rinvoq$64,260
- OMVOH$58,429
- VELSIPITY$39,930
- Cimzia$33,807
- INFLECTRA$16,875
- Idacio$4,880
- DIAGNOSTIC ULTRASOUND SYSTEM$2,859
- EUCRISA$2,275
- QuickVue$1,500
- CARDIOMEMS$1,040
- REMICADE$976
- Monoferric$712
How this compares
$1,601,325 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 121 | $3,296,238 |
| GattexTeduglutide | 24 | $1,092,050 |
| Humira(Cf) PenAdalimumab | 73 | $698,480 |
| Skyrizi On-BodyRisankizumab-Rzaa | 31 | $641,571 |
| RinvoqUpadacitinib | 35 | $313,675 |
| SimponiGolimumab | 28 | $306,692 |
| EntyvioVedolizumab | 22 | $194,545 |
| Omvoh PenMirikizumab-Mrkz | 15 | $151,666 |
| CreonLipase/Protease/Amylase | 15 | $61,693 |
| Mesalamine | 61 | $34,714 |
| XifaxanRifaximin | 11 | $24,774 |
| Mesalamine ErMesalamine | 22 | $18,104 |
| Opium Tincture | 14 | $5,976 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 28 | $4,721 |
| Colesevelam Hcl | 12 | $2,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Simponi | $140,663 | $3,602,930149 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex, Entyvio | $190,161 | $1,286,59546 claims |
| AbbVieRinvoq, Creon | $419,480 | $375,36850 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $386 | $24,77411 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $10,109 | $4,72128 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $4,914 | $7513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
- Isaac RaijmanHouston$565K
- Kalpesh PatelHouston$382K
- Victor Ankoma-SeyHouston$340K
- John VierlingHouston$270K
- George TriadafilopoulosHouston$192K
- Chukwuma EgwimHouston$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.